A Study of Belzutifan (MK-6482) in Combination with Palbociclib Versus Belzutifan Monotherapy in Participants with Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)

Trial Identifier: 6482-024
Sponsor: MSD
Start Date: August 2022
Primary Completion Date: July 2026
Study Completion Date: July 2026
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary

Trial Locations

Country Location
Australia, New South Wales Macquarie University, New South Wales, Australia, 2109
Australia, New South Wales Westmead, New South Wales, Australia, 2145
Australia, Victoria Frankston, Victoria, Australia, 3199
Australia, Western Australia Nedlands, Western Australia, Australia, 6009
Israel, N/A Afula, N/A, Israel, 1834111
Israel, N/A Haifa, N/A, Israel, 3109601
Israel, N/A Jerusalem, N/A, Israel, 9103102
Israel, N/A Petah Tikva, N/A, Israel, 4941492
Israel, N/A Tel Aviv, N/A, Israel, 6423906
United States, DC Washington, DC, United States, 20007
United States, IL Chicago, IL, United States, 60637
United States, MA Boston, MA, United States, 02215
United States, UT Salt Lake City, UT, United States, 84112